PHARMACEUTICAL IP

  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
    • Evolve AI
      • Albert (Validity)
        • Validity analysis
        • Albert Construe (Claim construction)
      • Popper (Prosecution)
      • Franklin (Publication review)
      • AI for Sequences
    • Fractional IP counsel
    • Services
      • AI guidance
      • Competitive intelligence
      • Deals
      • Due diligence
      • Freedom to operate
      • IP strategy and communication
      • Oppositions and appeals
      • Patent drafting
      • Patent prosecution
      • Trade secrets
    • Technologies
      • Pharmaceuticals
      • Biologics
      • Cell & gene therapy
      • AI drug discovery
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Fractional IP counsel
    • Fractional IP counsel
    • What is fractional IP counsel?
    • Our clients
      • Biotech
      • CROs and CMOs
      • Established pharma
      • International IP counsel
      • Investors
      • Start-ups
      • Universities
  • Evolve AI
    • Albert (Validity)
      • Validity analysis
      • Albert Construe (Claim construction)
    • Popper (Prosecution)
    • Franklin (Publication review)
    • AI for Sequences
  • Technologies
    • Pharmaceuticals
      • Dosing regimens
      • Formulations
      • Life cycle management
      • New indications
      • Platform technologies
    • Biologics
      • Antibodies
      • Antibody-drug conjugates (ADCs)
      • T cell engagers (TCEs)
    • Cell & gene therapy
      • CAR-T cell therapies
      • Gene therapies
      • In vivo CAR-T
      • Lipid nanoparticles (LNPs)
      • Macrophages (CAR-M)
      • mRNA therapeutics
      • Regenerative cell therapies
    • AI drug discovery
  • Insights
    • Articles
    • Pharma IP Toolkit
    • Evolve Guides
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Recognition
    • Join us
    • Contact us
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team
  • Offering
  • What is fractional IP counsel?
  • Evolve AI
  • Technologies
  • Insights
  • Our team

G 2/21 does not permit armchair inventing (T 0258/21)

  • Technology: Patent law, Pharmaceuticals
  • 1st December 2023
Does G 2/21 allow you to claim a new medical use for a known drug without any supporting data in your application? In T 0258/21, the Board of Appeal provided a decisive, and unsurprising, "no."
Single cut gold stone glowing turquoise at its heart on dark blue, Evolve abstract article image

Originally posted on IPKat.

Interpretations of G 2/21 by the EPO Boards of Appeal have so far been reasonably patentee-friendly. Boards of Appeal have interpreted G 2/21 as permitting patentees to rely on technical effects for which the application as filed is completely silent. The recent decision in T 0258/21, by contrast, is the first interpretation of G 2/21 leading to a finding of a lack of inventive step in view of an inadequate disclosure of the purported technical effect. However, T 0258/21 related to subject matter for which the EPO has always required additional evidence. Particularly, the claim in question was directed to a second medical use of a known therapeutic in a subpopulation of patients. The Board of Appeal considered there to be a complete lack of any convincing supporting data for the claimed use, either post-published or in the application as filed. The decision in T 0258/21 is therefore not surprising, and confirms that whilst G 2/21 is broadly favourable to patentees, it does not permit armchair inventing. 

T 0258/21: Case background

T 0258/21 related to the EP patent application EP 12716828.4. The application claimed clevidipine for the treatment of ischaemic stroke. Clevidipine is an anti-hypertensive drug marketed by Chiesi as Cleviprex. The closest prior art was identified as a journal article mentioning the use of clevidipine for the treatment of haemorrhagic stroke. The difference between the claimed invention and the closest prior art was identified as being that the invention related to ischaemic stroke instead of haemorrhagic stroke. Importantly, ischaemic and haemorrhagic strokes have very different causes. Ischaemic strokes are caused by blood clots blocking the supply of blood to the brain. Haemorrhagic strokes are caused by a ruptured blood vessel in the brain. Rather surprisingly for a medical use application, the application itself did not contain any data relating to the therapeutic effect. The original application was no more than 20 pages in length and didn’t include any data, examples or figures. In view of this rather sparse disclosure, the Board of Appeal concluded that “[n]o technical effect directly linked to the identified distinguishing feature, namely the reduction of ischemic stroke damage, has thus been demonstrated in the application documents“. 

Reliance on a post-hoc identified technical effect of medical use in the absence of any data 

On appeal, the applicant argued that the selection of clevidipine for the treatment of ischaemic stroke was inventive in view of the unexpected technical effect of clevidipine for the treatment of ischaemic stroke. Particularly, the applicant argued that clevidipine was surprisingly safe and efficacious in the treatment of ischaemic stroke compared to other anti-hypertensive agents. The applicant submitted post-filed data purporting to support this technical effect. 

However, the Board of Appeal was not convinced that either the application as filed or the post-filed data adequately supported the technical effect proposed by the applicant. First, with regards to whether it was even possible for the applicant to rely on the post-hoc technical effect, the Board of Appeal noted the order from G 2/21 that “a patent applicant or proprietor may rely upon a technical effect for inventive step if the skilled person, having the common general knowledge in mind, and based on the application as originally filed, would derive said effect as being encompassed by the technical teaching and embodied by the same originally disclosed invention“. 

For the Board of Appeal in the case in question, the technical effect on which the applicant was seeking to rely “was neither contemplated nor even suggested in the original application. Indeed the original application did not mention any comparison to other anti-hypertensive agents and it encompassed the treatment of both haemorrhagic and ischemic stroke […]. It follows that this technical effect relied upon by the applicant cannot be taken into account for the assessment of inventive step in accordance with G 2/21.” The Board of Appeal also noted that even if the purported technical effect could have been derivable from the original application, the additional submissions from the applicant purporting to support the technical effect did not “provide any detailed results nor any details on the protocols used […] The meaningfulness of the appellant’s exploitation of the data provided in these abstracts is therefore prima facie questionable.“

The Board of Appeal was thus not convinced that the technical effect on which the applicant wished to rely for inventive step was convincingly encompassed and embodied by the application as filed. The Board of Appeal went on to conclude that, in the absence of a surprising technical effect derivable from the application as filed (or even the post-filed data), it would be obvious in view of the prior art for a skilled person to select clevidipine for the treatment of ischaemic stroke. 

The applicant also found themselves in an inventive step / sufficiency squeeze in their attempt to argue that the prior art did not plausibly demonstrate the use of clevidipine to treat ischaemic stroke: 

“the Board underlines that, should the appellant’s unpredictability approach have been followed (i.e. the effect of clevidipine in the treatment of ischemic stroke damage in patients with ischemic stroke not be considered plausible on the basis of [the prior art]), an issue of lack of sufficiency of disclosure would have arisen since the original application does not provide any experimental data substantiating the claimed medical use.“

The Board of Appeal thus upheld the decision of the Examining Division to refuse the application. 

Analysis

The implementation of G 2/21 in this case could be said to contrast with previous decisions, in which G 2/21 has not been interpreted as preventing applicants from relying on a technical effect on which the application as filed is completely silent. However, none of the previous decisions interpreting G 2/21 have contemplated the evidence requirement for a technical effect for a biotech invention for which no supporting data or statements could be identified from any of the application as filed, common general knowledge (absent an obviousness squeeze) or post-published submissions.  

It is not a surprise that a second medical use claim may be refused by the EPO in view of the complete absence of any data, either in the original application or submitted post-filing, supporting the medical use. As has been discussed extensively in the context of the plausibility debate, second medical use inventions represent a class of invention where there is additional burden on the patentee to provide supporting evidence. In most cases, there will be substantial doubt over whether any particular substance or composition will be safe and efficacious at treating a particular disease, hence the need for long and protracted clinical trials and regulatory processes. It is therefore not surprising that patent offices require some evidence to support a medical use claim. G 2/21 has not changed this requirement. 

Related insights...

Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

Not just synergy: Other ways to support a drug combo invention (T 0593/24)

  • 17th November 2026
It is often necessary to support a drug combination invention with synergy data. This can be a problem for innovators, given that synergy data may not be assessed in the clinic, as additive effects may be sufficient for regulatory approval. However, T 0593/24 is a reminder that, if you lack synergy data, this may not…
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image
Gold band splitting into three branches at a turquoise junction on dark blue, Evolve abstract article image

Fractional IP counsel for biotech: what to look for in a fractional IP adviser

  • 16th November 2026
What to look for in part-time senior IP support for a growing biotech, from Series A to partnering and acquisition, and how experienced fractional IP counsel can help at every stage.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

Post-published clinical data does not always save you (T 0251/25, Empagliflozin)

  • 3rd November 2026
Empagliflozin (Jardiance) is approved in the US for reducing the risk of cardiovascular death in adults with type 2 diabetes (T2D) and established cardiovascular disease, and in Europe for reducing the risk of cardiovascular death and hospitalisation for heart failure in adults with heart failure. The recent decision in T 0251/25 nonetheless found Boehringer Ingelheim’s…
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image
Flight of gold steps with one turquoise glowing step on dark blue, Evolve abstract article image

Reformatio in peius survives a procedural violation (T 1168/24)

  • 2nd November 2026
Sometimes patent law is about procedures and not inventions. The appeal in T 1168/24 related to the lipid nanoparticle (LNP) technology behind the COVID-19 vaccines, opposed by Merck and Moderna. After two rounds of opposition and two appeals, the patent was revoked for added matter. Whilst the global litigation surrounding LNPs is interesting in its…
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

The enablement paradox and the danger of definitions (Wyeth v AstraZeneca)

  • 6th October 2026
The Federal Circuit’s decision in Wyeth v AstraZeneca (No. 2024-2325) applied the enablement test to a dose invention. The case is an interesting contrast to the other recent case to apply enablement to a method of treatment claim, Teva v Eli Lilly.
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image
Nested gold frames with a glowing turquoise centre on dark blue, Evolve abstract article image

Lack of clarity by the backdoor: An ambiguity “may simply result in a broader interpretation” (T 0977/25)

  • 4th October 2026
In T 0977/25, a Board of Appeal found that the word “it” in an amended method claim for an e-cigarette cartridge was ambiguous.
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image
Gold bar dissolving into turquoise fragments at its centre on dark blue, Evolve abstract article image

G1/25: What are the consequences?

  • 12th September 2026
Following the release of G1/25, questions have been circling as to what the decision means for the pending referral in G 1/26 and what the consequences (good or bad) are for applicants and patentees.
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image
Stack of gold plates fanning open around a turquoise light on dark blue, Evolve abstract article image

BREAKING: When real doubt hits – G1/25 changes the description adaptation requirement for the worse

  • 4th September 2026
G 1/25, issued today, holds that the description must be adapted only where an “inconsistency” between the claims and description causes non-compliance with another requirement of the EPC.
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image
Gold ribbon twisting once to reveal a turquoise underside on dark blue, Evolve abstract article image

New referral on claim interpretation and relevance of G1/24 to added matter confirmed (G1/26)

  • 23rd July 2026
We now have confirmation of a new referral to the EBA on claim interpretation (G1/26). As previously hinted, the Board of Appeal in T 0873/24 has decided to refer questions on the application of G1/24 to the assessment of added matter.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.
Gold block of two interlocking pieces with a turquoise joint on dark blue, Evolve abstract article image.

When do you file for a drug combination invention? (T 592/24)

  • 16th July 2026
Drug combination inventions are increasingly difficult to protect. File too early for a drug-combination invention and the application may lack the data to support the non-obvious effect of the combination. Wait for the trial read-out, and a competitor, or your own published protocol, may have already placed the invention in the public domain. 
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice
  • Subscribe
  • Contact us
  • Cookie Notice
  • Complaints Procedure
  • Privacy notice